Human Antibodies & Hybridomas

31 March – 2 April 2014, Federation of Austrian Industry, Industriehaus-Verein, Schwarzenbergplatz 4, A-1030 Vienna, Austria

  • Increase font size
  • Default font size
  • Decrease font size

Introduction

Sponsored by the International Journal Human Antibodies
In association with the Integrative Medical Sciences Association

The 18th HUMAN ANTIBODIES & HYBRIDOMAS conference will be held at The Austrian Industrial Association, Vienna, Austria.

The HAH 2014 scientific programme will include keynote lectures, contributed papers and poster presentations emphasising all key aspects of human antibody and hybridoma technology, applications and engineering.

The HAH 2014 Scientific Advisory Committee are therefore encouraging submissions to be considered for the ‘Therapeutic Antibodies’ sessions at HAH 2014.

Antibodies Applications and New Developments

Scientific Advisory Committee

Programme Chairman: Professor Mark Glassy (IMSA, San Diego, USA)

Local Conference Chairman: Hermann Katinger (Polymun Scientific Immunbiologische Forschung GmbH, Vienna, Austria)

Mirek Gorny (New York University School of Medicine, New York, USA)
Zdenka L. Jonak (GlaxoSmithKline, USA)
Henry Lowman (CytomX Therapeutics Inc., South San Francisco, California, USA)
J. Donald Capra (OMRF, USA)
Roberto Burioni (Universita Vita-Salute San Raffaele, Milan, Italy)
Kathy Potter (Southampton University, UK)
Jim Larrick (Panorama Research Inc., USA)
Alois Lang (GeNeuro SA, Geneva, Switzerland)
David P. Humphreys (UCB, Slough, UK)
Markus Enzelberger (MorphoSys AG, Martinsried, Germany)
Eszter Nagy (Arsanis GmbH, Vienna, Austria)
Sachdev Sidhu (University of Toronto, Canada)
John Haurum (F-star, Cambridge, UK)
Paul Kerr (Fusion Antibodies, Northern Ireland, UK)
Yan Wu (Kadmon Pharmaceuticals LLC, New York, USA)
Bob Kelley (Genentech Inc., South San Francisco, USA)
David Naor (The Hebrew University, Jerusalem, Israel)
Lynn MacDonald (Regeneron Pharmaceuticals, Tarrytown, New York, USA)
Jody Berry (Becton Dickinson, La Jolla, California, USA)
Manuel Baca (MedImmune Inc., Gaithersburg, Maryland, USA)
Jean-Luc Teillaud (INSERM/Cordeliers Research Centre, Paris, France)
Dale Ludwig (ImClone Inc., New York, USA)
Dietmar Katinger (Polymun Scientific Immunbiologische Forschung GmbH, Vienna, Austria)

Conference Scope

The scope of the HAH 2014 conference falls broadly into nine main session categories:

  • Infectious Diseases
  • Autoimmunity
  • Molecular Biology
  • Emerging Technologies
  • Clinical Applications
  • Therapeutic Antibodies
  • Cancer
  • Anti-Infective Antibodies
  • Intellectual Property & Legal Issues

HAH 2014 will be placing special emphasis on and devoting at least one day of the 2012 conference to presentations covering Therapeutic Antibodies to include:

  • Preclinical Issues
  • Manufacturing/Stabilization
  • Clinical Issues
  • Regulatory and IP Issues
 

HAH 2014 Delegates

Login details will be supplied after you have registered for the event.


HAH 2014 Sponsors

  • Nascent Biologics
  • Fusion Antibodies
  • Morphosys
  • F-star
  • Polymun Scientific
  • Aldevron
  • ModiQuest Research
  • Fenwick & West
  • VIBT-BOKU
  • ImClone Systems
  • ImmunoGen
  • OMT
  • MacroGenics
  • MedImmune
  • MAB Discovery
  • InCellart
  • Adimab
  • CytomX Therapeutics
  • Regeneron
  • Catalent
  • FWF
  • Arsanis Biosciences
  • Boehringer Ingelheim
  • Merck Serono
  • BioToP
  • Symphogen
  • UCB
  • Mapp Biopharmaceutical
  • Retroscreen Virology
  • Kadmon
  • Geneuro

HAH 2014 Downloads

HAH 2014 Leaflet

HAH 2014 Mailing List

Name
E-mail Address
What is 1+4-2?